Loren Alison W, Tsai Donald E
Division of Hematology/Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Clin Chest Med. 2005 Dec;26(4):631-45, vii. doi: 10.1016/j.ccm.2005.06.014.
Post-transplant lymphoproliferative disorder (PTLD) is an increasingly recognized complication of solid organ and hematopoietic stem cell transplantation. PTLD represents a spectrum of polyclonal and monoclonal lymphoproliferation, generally of B cells. Prompt diagnosis is key and requires a high index of suspicion. An increasing variety of highly effective therapies, including immune modulation via reduction in immunosuppression, monoclonal antibodies, and cellular therapy, have dramatically improved the cure rates of this once devastating disease.
移植后淋巴细胞增生性疾病（PTLD）是实体器官和造血干细胞移植中一种日益受到重视的并发症。PTLD表现为一系列多克隆和单克隆淋巴细胞增生，通常为B细胞。及时诊断是关键，需要高度的怀疑指数。越来越多的高效治疗方法，包括通过减少免疫抑制进行免疫调节、单克隆抗体和细胞治疗，显著提高了这种曾经具有毁灭性的疾病的治愈率。
